Abstract：【Objective】 To investigate the efficacy of irinotecan combined with capecitabine and bevacizumab in patients with colorectal cancer and liver metastases. 【Methods】 A total of 100 patients with colorectal cancer and liver metastases were randomly divided into an observation group and a control group, with 50 cases in each group. The observation group received irinotecan + capecitabine + bevacizumab, while the control group received oxaliplatin + capecitabine + bevacizumab. Clinical efficacy, serum vascular endothelial growth factor (VEGF) and carbohydrate antigen 19-9 (CA19-9) levels before and after treatment, as well as the incidence of adverse reactions were compared between the two groups. 【Results】 There were no statistically significant differences between the two groups in overall response rate or disease control rate (P>0.05). After treatment, VEGF and CA19-9 levels in the observation group were lower than those in the control group (P<0.05). During an 18-month follow-up, the progression-free survival (PFS) was 9.2 months and 8.1 months, and the median overall survival (OS) was 20.5 months and 19.1 months in the observation and control groups, respectively; no statistically significant differences were found between the two groups (P>0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】 Irinotecan + capecitabine + bevacizumab shows similar efficacy and good safety compared with oxaliplatin + capecitabine + bevacizumab in patients with colorectal cancer and liver metastases; however, the observation group demonstrated greater improvements in serum VEGF and CA19-9 levels.
朱静. 伊立替康联合卡培他滨和贝伐珠单抗治疗结直肠癌伴肝转移患者的疗效[J]. 医学临床研究, 2026, 43(3): 425-427.
ZHU Jing. Efficacy of Irinotecan Combined with Capecitabine and Bevacizumab in Patients with Colorectal Cancer and Liver Metastases. JOURNAL OF CLINICAL RESEARCH, 2026, 43(3): 425-427.
2026, Vol. 43 
